People with, FAP, an inherited condition that greatly increases their risk of gastrointestinal cancer who took a combination of erlotinib (Tarceva) and sulindac (Aflodac) saw a decrease in the number of precancerous lesions in the colon and rectum.
http://ift.tt/2pbh0XD
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου